Market Cap | 1.97B | P/E | - | EPS this Y | 67.50% | Ern Qtrly Grth | - |
Income | -278.43M | Forward P/E | -11.45 | EPS next Y | -34.10% | 50D Avg Chg | -11.00% |
Sales | 65.86M | PEG | 0.60 | EPS past 5Y | - | 200D Avg Chg | 4.00% |
Dividend | N/A | Price/Book | 2.77 | EPS next 5Y | -10.76% | 52W High Chg | -38.00% |
Recommedations | 2.30 | Quick Ratio | 2.19 | Shares Outstanding | 224.31M | 52W Low Chg | 57.00% |
Insider Own | 45.27% | ROA | -24.52% | Shares Float | 123.54M | Beta | 2.62 |
Inst Own | 20.14% | ROE | -54.30% | Shares Shorted/Prior | 5.51M/5.65M | Price | 8.82 |
Gross Margin | -131.00% | Profit Margin | - | Avg. Volume | 695,441 | Target Price | 8.00 |
Oper. Margin | -493.58% | Earnings Date | Nov 12 | Volume | 129,216 | Change | -2.97% |
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
JMP Securities | Market Outperform | Sep 16, 24 |
JMP Securities | Market Outperform | Aug 16, 24 |
JMP Securities | Market Outperform | Jul 3, 24 |
Leerink Partners | Market Perform | Apr 25, 24 |
Guggenheim | Neutral | Apr 5, 24 |
Guggenheim | Buy | Apr 26, 21 |
Credit Suisse | Underperform | Dec 10, 20 |
B of A Securities | Buy | Sep 8, 20 |
Jefferies | Hold | Sep 8, 20 |